NCT06703606View on ClinicalTrials.gov

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 13, 2025

Primary Completion Date

May 5, 2027

Study Completion Date

May 5, 2027

Conditions
Severe Hemophilia A
Interventions
DRUG

MARSTACIMAB

Marstacimab 150 mg administered subcutaneous (SC) once weekly (QW)

Trial Locations (1)

90007

RECRUITING

Orthopaedic Institute for Children, Los Angeles

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY